SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Unax Lertxundi, Arantxazu Isla Ruiz, María Ángeles Solinís Aspiazu, Saioa Domingo-Echaburu, Montserrat García, Carmelo Aguirre, Juan Carlos García-Moncó, Adverse Reactions to Antipsychotics in Parkinson Disease, Clinical Neuropharmacology, 2015, 1

    CrossRef

  2. 2
    Isabelle Beaulieu-Boire, Anthony E. Lang, Behavioral effects of levodopa, Movement Disorders, 2015, 30, 1
  3. 3
    Jacopo Vittoriano Bizzarri, Giancarlo Giupponi, Ignazio Maniscalco, Patrizia Schroffenegger, Andreas Conca, Hans Peter Kapfhammer, Parkinson-Krankheit und Psychosen, neuropsychiatrie, 2015, 29, 1, 1

    CrossRef

  4. 4
    K. Wenzel, Nicht motorische Symptome bei Morbus Parkinson, psychopraxis. neuropraxis, 2014, 17, 4, 23

    CrossRef

  5. 5
    Martin Broadstock, Clive Ballard, Anne Corbett, Novel pharmaceuticals in the treatment of psychosis in Parkinson’s disease, Expert Review of Clinical Pharmacology, 2014, 7, 6, 779

    CrossRef

  6. 6
    Barbara Connolly, Susan H. Fox, Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease, Neurotherapeutics, 2014, 11, 1, 78

    CrossRef

  7. 7
    Jennifer G. Goldman, Samantha Holden, Treatment of Psychosis and Dementia in Parkinson’s Disease, Current Treatment Options in Neurology, 2014, 16, 3

    CrossRef

  8. 8
    Joseph H Friedman, Pimavanserin for the treatment of Parkinson's disease psychosis, Expert Opinion on Pharmacotherapy, 2013, 14, 14, 1969

    CrossRef

  9. 9
    ROSA QUELHAS, Psychiatric Care in Parkinson’s Disease, Journal of Psychiatric Practice, 2013, 19, 2, 118

    CrossRef

  10. You have free access to this content10
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  11. 11
    Thien Thien Lim, Kelvin L. Chou, Hubert H. Fernandez, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  12. 12
    Thien Lim, Kelvin Chou, Hubert Fernandez, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  13. 13
    Arvid Rongve, Eirik Auning, Uwe Ehrt, Dag Årsland, Psykose ved Parkinsons sykdom, Tidsskrift for Den norske legeforening, 2012, 132, 2, 155

    CrossRef

  14. 14
    K. Bloomfield, L. MacDonald, G. Finucane, B. Snow, R. Roxburgh, Use of antipsychotic medications in patients with Parkinson's disease at Auckland City Hospital, Internal Medicine Journal, 2012, 42, 7
  15. 15
    Jennifer G Goldman, Christina L Vaughan, Christopher G Goetz, An update expert opinion on management and research strategies in Parkinson's disease psychosis, Expert Opinion on Pharmacotherapy, 2011, 12, 13, 2009

    CrossRef

  16. 16
    Joseph H Friedman, Managing psychosis in Parkinson’s disease, Neurodegenerative Disease Management, 2011, 1, 3, 217

    CrossRef

  17. 17
    Jennifer G. Goldman, New Thoughts on Thought Disorders in Parkinson's Disease: Review of Current Research Strategies and Challenges, Parkinson's Disease, 2011, 2011, 1

    CrossRef

  18. 18
    Klaus Seppi, Daniel Weintraub, Miguel Coelho, Santiago Perez-Lloret, Susan H. Fox, Regina Katzenschlager, Eva-Maria Hametner, Werner Poewe, Olivier Rascol, Christopher G. Goetz, Cristina Sampaio, The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease, Movement Disorders, 2011, 26, S3
  19. 19
    Philippe Huot, Susan H. Fox, Jonathan M. Brotchie, The serotonergic system in Parkinson's disease, Progress in Neurobiology, 2011, 95, 2, 163

    CrossRef

  20. 20
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  21. 21
    Marty L. Eng, Timothy E. Welty, Management of hallucinations and psychosis in Parkinson's disease, The American Journal of Geriatric Pharmacotherapy, 2010, 8, 4, 316

    CrossRef

  22. 22
    Roberto Ceravolo, Carlo Rossi, Lorenzo Kiferle, Ubaldo Bonuccelli, Nonmotor symptoms in Parkinson’s disease: the dark side of the moon, Future Neurology, 2010, 5, 6, 851

    CrossRef

  23. 23
    Joseph H. Friedman, Parkinson’s disease psychosis 2010: A review article, Parkinsonism & Related Disorders, 2010, 16, 9, 553

    CrossRef

  24. 24
    Laura B. Zahodne, Hubert H. Fernandez, Parkinson’s Psychosis, Current Treatment Options in Neurology, 2010, 12, 3, 200

    CrossRef

  25. 25
    Matthias Löhle, Alexander Storch, Heinz Reichmann, Beyond tremor and rigidity: non-motor features of Parkinson’s disease, Journal of Neural Transmission, 2009, 116, 11, 1483

    CrossRef

  26. 26
    Heinz Reichmann, Christine Schneider, Matthias Löhle, Non-motor features of Parkinson's disease: depression and dementia, Parkinsonism & Related Disorders, 2009, 15, S87

    CrossRef

  27. 27
    Mehrul Hasnain, W. Victor R. Vieweg, Mark S. Baron, Mary Beatty-Brooks, Antony Fernandez, Anand K. Pandurangi, Pharmacological Management of Psychosis in Elderly Patients with Parkinsonism, The American Journal of Medicine, 2009, 122, 7, 614

    CrossRef

  28. 28
    Ludy Shih, Daniel Tarsy, Pharmacology and Therapeutics, 2009,

    CrossRef

  29. 29
    Urs Peter Mosimann, Daniel Collerton, Robert Dudley, Thomas Daniel Meyer, Gemma Graham, Jennifer Louise Dean, Daniel Bearn, Alison Killen, Lucy Dickinson, Mike Patrick Clarke, Ian Grant McKeith, A semi-structured interview to assess visual hallucinations in older people, International Journal of Geriatric Psychiatry, 2008, 23, 7
  30. 30
    Christopher G. Goetz, Wenqing Fan, Sue Leurgans, Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening, Movement Disorders, 2008, 23, 11
  31. 31
    Laura B Zahodne, Hubert H Fernandez, Pathophysiology and Treatment of Psychosis in Parkinson’s Disease, Drugs & Aging, 2008, 25, 8, 665

    CrossRef

  32. 32
    Ubaldo Bonuccelli, Roberto Ceravolo, The safety of dopamine agonists in the treatment of Parkinson's disease, Expert Opinion on Drug Safety, 2008, 7, 2, 111

    CrossRef

  33. 33
    Richard Camicioli, Serge Gauthier, Clinical Trials in Parkinson's Disease Dementia and Dementia with Lewy Bodies, The Canadian Journal of Neurological Sciences, 2007, 34, S1, S109

    CrossRef

  34. 34
    Nuria Caballol, Maria J Martí, Eduardo Tolosa, Cognitive dysfunction and dementia in Parkinson disease, Movement Disorders, 2007, 22, S17
  35. 35
    Maria J. Martí, Eduardo Tolosa, Andres de la Cerda, Dementia in Parkinson's disease, Journal of Neurology, 2007, 254, S5, 41

    CrossRef

  36. 36
    Kelvin L Chou, Joseph H Friedman, Drug-induced parkinsonism in the elderly, Future Neurology, 2007, 2, 3, 307

    CrossRef

  37. 37
    Leora L Borek, Kelvin L Chou, Joseph H Friedman, Management of the behavioral aspects of Parkinson’s disease, Expert Review of Neurotherapeutics, 2007, 7, 6, 711

    CrossRef

  38. 38
    Marco Onofrj, Astrid Thomas, Laura Bonanni, New approaches to understanding hallucinations in Parkinson’s disease: phenomenology and possible origins, Expert Review of Neurotherapeutics, 2007, 7, 12, 1731

    CrossRef

  39. 39
    Rita Moretti, Paola Torre, Cristina Vilotti, Rodolfo M. Antonello, Gilberto Pizzolato, Rivastigmine and Parkinson dementia complex, Expert Opinion on Pharmacotherapy, 2007, 8, 6, 817

    CrossRef

  40. 40
    Kelvin L Chou, Leora L Borek, Joseph H Friedman, The management of psychosis in movement disorder patients, Expert Opinion on Pharmacotherapy, 2007, 8, 7, 935

    CrossRef

  41. 41
    M. Emre, Treatment of dementia associated with Parkinson's disease, Parkinsonism & Related Disorders, 2007, 13, S457

    CrossRef

  42. 42
    Murat Emre, Parkinson's Disease and Related Disorders, Part I, 2007,

    CrossRef

  43. 43
    Caroline H Williams-Gray, Thomas Foltynie, Simon J G Lewis, Roger A Barker, Cognitive Deficits and Psychosis in Parkinson???s Disease, CNS Drugs, 2006, 20, 6, 477

    CrossRef

  44. 44
    Kelvin L Chou, Hubert H Fernandez, Combating psychosis in Parkinson’s disease patients: the use of antipsychotic drugs, Expert Opinion on Investigational Drugs, 2006, 15, 4, 339

    CrossRef

  45. 45
    Joseph H. Friedman, Robert M. Berman, Christopher G. Goetz, Stewart A. Factor, William G. Ondo, Joanne Wojcieszek, William H. Carson, Ronald N. Marcus, Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease, Movement Disorders, 2006, 21, 12
  46. You have free access to this content46
    M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol, C. Sampaio, Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease, European Journal of Neurology, 2006, 13, 11
  47. 47
    J.C. Dumville, S. Hahn, J.N.V. Miles, D.J. Torgerson, The use of unequal randomisation ratios in clinical trials: A review, Contemporary Clinical Trials, 2006, 27, 1, 1

    CrossRef

  48. 48
    Kelvin L Chou, Joseph H Friedman, Use of atypical antipsychotics in neurodegenerative diseases, Future Neurology, 2006, 1, 5, 553

    CrossRef

  49. 49
    William G. Ondo, Ron Tintner, Kevin Dat Voung, Dejian Lai, George Ringholz, Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease, Movement Disorders, 2005, 20, 8
  50. 50
    Daniel Weintraub, Ira R. Katz, Pharmacologic Interventions for Psychosis and Agitation in Neurodegenerative Diseases: Evidence About Efficacy and Safety, Psychiatric Clinics of North America, 2005, 28, 4, 941

    CrossRef

  51. 51
    Hasmet A. Hanagasi, Murat Emre, Treatment of behavioural symptoms and dementia in Parkinson's disease, Fundamental & Clinical Pharmacology, 2005, 19, 2
  52. 52
    Werner Poewe, Treatment of dementia with Lewy bodies and Parkinson's disease dementia, Movement Disorders, 2005, 20, S12
  53. 53
    Joseph H. Friedman, Hubert H. Fernandez, Animal Models of Movement Disorders, 2005,

    CrossRef

  54. 54
    Jack J. Chen, Anxiety, depression, and psychosis in Parkinson's disease: unmet needs and treatment challenges, Neurologic Clinics, 2004, 22, 3, S63

    CrossRef

  55. 55
    Richard M. Trosch, Neuroleptic-Induced Movement Disorders: Deconstructing Extrapyramidal Symptoms, Journal of the American Geriatrics Society, 2004, 52,
  56. 56
    Richard Camicioli, Nancy Fisher, Progress in Clinical Neurosciences: Parkinson's Disease with Dementia and Dementia with Lewy Bodies, The Canadian Journal of Neurological Sciences, 2004, 31, 01, 7

    CrossRef

  57. 57
    JLW Bosboom, ECh Wolters, Psychotic symptoms in Parkinson’s disease: pathophysiology and management, Expert Opinion on Drug Safety, 2004, 3, 3, 209

    CrossRef

  58. 58
    Jorge L. Juncos, Vicki J. Roberts, Marian L. Evatt, Rita D. Jewart, Colleen D. Wood, Larry S. Potter, Hann-Chang Jou, Paul P. Yeung, Quetiapine improves psychotic symptoms and cognition in Parkinson's disease, Movement Disorders, 2004, 19, 1
  59. 59
    Edward C. Lauterbach, The neuropsychiatry of Parkinson's disease and related disorders, Psychiatric Clinics of North America, 2004, 27, 4, 801

    CrossRef

  60. 60
    Victoria S. Pelak, Grant T. Liu, Visual hallucinations, Current Treatment Options in Neurology, 2004, 6, 1, 75

    CrossRef

  61. 61
    Dag Aarsland, Uwe Ehrt, Basal ganglia diseases and geriatric psychiatry: a new approach, Current Opinion in Psychiatry, 2003, 16, 6, 621

    CrossRef

  62. 62
    Current Awareness in Human Psychopharmacology, Human Psychopharmacology: Clinical and Experimental, 2003, 18, 2
  63. 63
    Ron Tintner, Joseph Jankovic, Dopamine agonists in Parkinson’s disease, Expert Opinion on Investigational Drugs, 2003, 12, 11, 1803

    CrossRef

  64. 64
    David R.P. Guay, Emily R. Hajjar, Geriatric pharmacotherapy updates, The American Journal of Geriatric Pharmacotherapy, 2003, 1, 2, 96

    CrossRef

  65. 65
    Werner Poewe, Psychosis in Parkinson's disease, Movement Disorders, 2003, 18, S6
  66. 66
    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Late (Complicated) Parkinson's Disease,
  67. 67
    Joseph H. Friedman, Psychosis in Parkinson's Disease,
  68. 68
    Murat Emre, Treatment of Dementia Associated with Parkinson's Disease,